MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Massimiliano Mirabella, Viviana Nociti, Stefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, Elisabetta Signoriello, Giacomo Lus, Simona Bonavita, Gianmarco Abbadessa, Luigi Lavorgna, Giorgia Teresa Maniscalco, Erica Curti, Lorena Lorefice, Eleonora Cocco, Damiano Baroncini, Giorgia Mataluni, Doriana Landi, Martina Petruzzo, Roberta Lanzillo, Ilaria GandogliaAlice Laroni, Rita Frangiamore, Arianna Sartori, Paola Cavalla, Gianfranco Costantini, Ruggero Capra, Maria Pia Sormani, Marinella Clerico

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

Background: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID). Methods: Observational, multicentre, retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Three hundred and sixteen patients were enrolled. The median dose interval (MDI) following the 24th infusion was 5 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Patients were grouped into 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Results: One hundred and eighty-seven patients were in the SID group (MDI = 4.5 weeks) and 129 in the EID group (MDI 6.1 weeks). The risk to develop active lesions on MRI is similar in SID and EID groups during the 6 and 12 months after the 24th natalizumab infusion, respectively 4.27% (95% CI:0.84–7.70) vs 4.71% (95% CI:0.16–9.25%) [p = 0.89] and 8.50% (95% CI:4.05–12.95) vs 6.55% (95% CI:2.11–11.00%) [p = 0.56]. The EID regimen does not appear to increase the occurrence of MRI activity during follow-up. Conclusion: There is no evidence of the reduced efficacy of natalizumab in an EID setting regarding the MRI activity. This observation supports the need for a bigger randomized study to assess the need to change the standard of the natalizumab dosing schedule, to better manage JCV-positive patients.
Lingua originaleEnglish
pagine (da-a)117385-N/A
RivistaJournal of the Neurological Sciences
Volume424
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Efficacy
  • Extended dose
  • Natalizumab
  • Multiple sclerosis
  • Magnetic resonance imaging

Fingerprint Entra nei temi di ricerca di 'MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study'. Insieme formano una fingerprint unica.

Cita questo